6.6 Long-Term Care, Hospice & Home Infusion Pharmacy Regulations

Navigating Pharmacy Regulations in LTC, Hospice, and Home Infusion

Pharmacy practice outside of traditional retail and hospital settings presents unique regulatory landscapes. Long-Term Care Facilities (LTCFs), hospices, and home infusion services cater to highly vulnerable patient populations who require specialized medication management. The Georgia State Board of Pharmacy, often in conjunction with federal regulations like those from the Centers for Medicare & Medicaid Services (CMS), imposes specific rules to ensure the safety and efficacy of pharmaceutical care in these specialized environments.

Long-Term Care Facilities (LTCFs) and the Consultant Pharmacist

In Long-Term Care Facilities, residents often take multiple medications for chronic conditions, increasing the risk of adverse drug events, drug interactions, and polypharmacy. To mitigate these risks, the role of the Consultant Pharmacist is legally mandated and critically important.

The Monthly Medication Regimen Review

One of the most heavily tested concepts regarding LTCFs on the MPJE is the requirement for the monthly medication regimen review (MRR).

• The Mandate: Federal law (and mirrored by state requirements) mandates that a licensed consultant pharmacist must review the medication regimen of each resident in the facility at least once a month.
• The Objective: The primary goal of the MRR is to identify, prevent, and resolve medication-related problems. The consultant pharmacist acts as an independent clinical auditor.
• What the Review Entails: During the monthly review, the pharmacist must meticulously examine the patient's chart, looking for specific irregularities. These include:
  • Polypharmacy: Is the patient taking unnecessary medications? Can any drugs be safely discontinued?
  • Appropriate Indications: Does every prescribed medication have a documented clinical indication?
  • Duplicate Therapy: Is the patient receiving multiple drugs from the same therapeutic class without a valid clinical reason?
  • Dosing and Duration: Are the doses appropriate for the patient's age, weight, and renal/hepatic function? Is the duration of therapy appropriate?
  • Drug Interactions: Are there any significant drug-drug, drug-disease, or drug-food interactions?
  • Adverse Drug Reactions (ADRs): Is the patient experiencing side effects that might be misdiagnosed as a new medical condition (the prescribing cascade)?
  • Laboratory Monitoring: For drugs requiring therapeutic monitoring (e.g., warfarin, phenytoin, digoxin), are the necessary labs being ordered and reviewed?
• Reporting Irregularities: If the consultant pharmacist identifies any irregularities, they are legally required to report them. These reports must be made in writing to the resident's attending physician and the facility's director of nursing. The physician is then required to document that they have reviewed the pharmacist's report and must provide a rationale if they choose not to implement the pharmacist's recommendations.

Emergency Kits in LTCFs

Because LTCFs do not typically have an on-site pharmacy, they must have a mechanism for accessing emergency medications immediately. This is accomplished through emergency kits.

• Ownership and Provision: The emergency kit is provided by a designated vendor pharmacy. Crucially, the drugs within the emergency kit remain the property of the supplying pharmacy until they are actually administered to a patient.
• Sealing and Security: Similar to hospital rules, LTCF emergency kits must be sealed with a tamper-evident seal and stored in a secure area to prevent unauthorized access and diversion.
• Access and Documentation: The kit may only be opened by authorized personnel (usually a registered nurse) upon receiving a valid, immediate-need prescription order from a physician. When the kit is opened, a record must be made indicating the patient's name, the prescriber, the drug administered, the date, and the time.
• Notification and Replacement: Once the seal is broken, the facility must notify the supplying pharmacy within a strictly defined timeframe (often within 24 to 72 hours, depending on specific state interpretations). The pharmacy must then promptly restock the used medications, verify the contents, and apply a new tamper-evident seal to ensure the kit is ready for the next emergency.

The Medicare Part D 14-Day Dispensing Cycle

To address the significant issue of medication waste in LTCFs (e.g., when a patient's medication is changed, or the patient is discharged or passes away, resulting in large quantities of discarded drugs), CMS implemented the 14-day dispensing rule for Medicare Part D patients residing in LTCFs.

• The Rule: Pharmacies dispensing to LTCFs are generally required to dispense solid oral doses of brand-name medications in cycles of 14 days or less, rather than the traditional 30-day supply.
• The Rationale: By dispensing smaller quantities more frequently, less medication is wasted if a therapy is altered or discontinued.
• Exceptions: There are important exceptions to the 14-day rule. It primarily applies to brand-name solid oral dosage forms. It generally does not apply to generic drugs (where the cost of frequent dispensing might outweigh the savings of reduced waste), liquids, antibiotics, or drugs that are difficult to dispense in 14-day increments (like certain original packaging or inhalers).

Hospice Pharmacy Services

Hospice care focuses on palliation and comfort for terminally ill patients. Pharmacy services in this setting have specific allowances to ensure pain and symptoms are managed rapidly.

• Emergency Kits: Hospices are also permitted to maintain emergency kits for the rapid initiation of symptom control (e.g., pain, nausea, anxiety). The rules regarding sealing and pharmacy ownership apply.
• Schedule II Prescriptions: Recognizing the acute need for pain management, federal and state laws often allow for more flexible transmission of Schedule II prescriptions for hospice patients. A faxed prescription for a Schedule II narcotic may serve as the original prescription if it is explicitly noted on the prescription that the patient is a hospice patient.

Home Infusion Pharmacy

Home infusion pharmacies prepare and dispense intravenous medications for administration in the patient's home. This requires rigorous adherence to sterile compounding standards.

• USP 797 Compliance: Home infusion pharmacies must strictly comply with all provisions of USP Chapter 797 regarding the compounding of sterile preparations. This includes facility design (cleanrooms, laminar airflow workbenches), personnel training, garbing procedures, and environmental monitoring to prevent contamination.
• 24/7 Availability: Because patients are receiving complex therapies (like Total Parenteral Nutrition or continuous IV antibiotics) at home, home infusion pharmacies are required to provide 24/7 on-call pharmacist support. A pharmacist must be accessible around the clock to address clinical questions, pump malfunctions, or adverse reactions.
• Patient Training and Nursing Coordination: The pharmacy must ensure that patients or their caregivers receive comprehensive training on how to store the medications, operate the infusion pumps, and recognize signs of infection or complications. This often requires close coordination with home health nursing agencies.

Mastering these specialized regulations is essential for understanding the full spectrum of pharmacy practice regulated by the state of Georgia.